Galibra’s GAD-005 gene therapy designated orphan drug

Galibra Neuroscience Inc.’s investigational gene therapy for succinic semialdehyde dehydrogenase (SSADH) deficiency, GAD-005, has been awarded orphan drug and rare pediatric disease designations by the FDA.